Website Under Maintenance

Clarke

Website Under Maintenance

Newsroom

Our site is down for scheduled maintenance. We are working to update our network to better provide the page you requested. We understand the inconvenience this may cause, but rest assured, we are doing everything we can to bring the site back online after our necessary updates.

Terms of Service Privacy Policy
© Copyright 2000-2024 Clarke Broadcasting Corporation. All rights reserved.
Feedback
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vaccinex, Inc. - Common Stock (NQ:VCNX)

1.410 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.410
Bid (Size) 1.320 (1)
Ask (Size) 1.460 (2)
Prev. Close 1.410
Today's Range 1.410 - 1.410
52wk Range 1.390 - 4.810
Shares Outstanding 65,941,086
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with improved pathologic response. 
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)
From Vaccinex, Inc.
Via GlobeNewswire

Performance

YTD
N/A
N/A
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
N/A
N/A
1 Year
-58.0%
-58.0%

More News

Read More
VCNX Stock Earnings: Vaccinex Reported Results for Q2 2024
Via InvestorPlace
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
From Vaccinex, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Vaccinex Faces Nasdaq Delisting: What's Going On With The Stock?
Via Benzinga
Crude Oil Down Over 1%; US Industrial Production Declines In November
Via Benzinga
Dow Dips Over 200 Points; US Retail Sales Top Estimates
Via Benzinga
Topics Stocks
Vaccinex Announces Receipt of Delisting Notification from Nasdaq
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
From Vaccinex, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024
From Vaccinex, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
What's Going On With Vaccinex Stock Wednesday?
Via Benzinga
Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership
From Vaccinex, Inc.
Via GlobeNewswire
Around $3M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Why DoorDash Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
From Vaccinex, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Vaccinex, Inc. - Common Stock publicly traded?
Yes, Vaccinex, Inc. - Common Stock is publicly traded.
What exchange does Vaccinex, Inc. - Common Stock trade on?
Vaccinex, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vaccinex, Inc. - Common Stock?
The ticker symbol for Vaccinex, Inc. - Common Stock is VCNX on the Nasdaq Stock Market
What is the current price of Vaccinex, Inc. - Common Stock?
The current price of Vaccinex, Inc. - Common Stock is 1.410
When was Vaccinex, Inc. - Common Stock last traded?
The last trade of Vaccinex, Inc. - Common Stock was at 12/17/24 04:00 PM ET
What is the market capitalization of Vaccinex, Inc. - Common Stock?
The market capitalization of Vaccinex, Inc. - Common Stock is 92.98M
How many shares of Vaccinex, Inc. - Common Stock are outstanding?
Vaccinex, Inc. - Common Stock has 93M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.